Aulos Bioscience, a US immuno-oncology company, has begun dosing patients in a trial combining avelumab (Bavencio) with imneskibart for treating non-small cell lung cancer.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
Aulos Bioscience doses first patient in avelumab lung cancer trial
